Market

Takeda vs. Ionis: Which Cathie Wood Pharmaceutical Stock is a Better Buy? By StockNews

© Reuters. Takeda vs. Ionis: Which Cathie Wood Pharmaceutical Stock is a Better Buy?

Stock-picker Cathie Wood expects pharmaceutical companies to deliver solid growth in 2021, given the rapid integration of tech and their continuing product innovations. Two top holdings in Wood’s Ark Genomic ETF (ARKG) are Takeda Pharmaceutical (TAK) and Ionis Pharmaceuticals (NASDAQ:). But which of the two pharma stocks is a better buy? Read on to find out.Takeda Pharmaceutical Company Limited (NYSE:) specializes in developing treatments in the fields of neuroscience, gastroenterology, oncology and other rare hereditary diseases. Headquartered in Japan, the company has multiple research facilities and strategic collaborative agreements with multiple research-based pharmaceutical companies worldwide. Renowned investor Cathie Wood held 15.94 million shares of TAK as of May 26. This represents a 0.64% weighting in the Ark Genomic Revolution ETF (ARKG).

Ionis Pharmaceuticals, Inc. (IONS) is an RNA-targeted therapeutics developer based in the United States. The company develops oral medications for the treatment and management of rare life-threatening diseases and lifelong ailments. Wood owns 7.86 million shares of IONS (as of May 26), representing a 0.65% weighting in the ARKG ETF. Ark Investment has a 5.58% stake in IONS.

Wood is betting on the capacity of genomics to shape the healthcare industry in 2021. The progress made by various companies in the field of DNA sequencing should allow them to develop cures for serious life-threatening diseases, such as cancer and lifelong ailments. In a CNBC interview, Wood said, “DNA sequencing is going to introduce science into healthcare decision making for the first time…We’re going to be able to cure diseases that we never thought it would be possible to cure, including cancer.” TAK and IONS have been making substantial progress on this front. And as the tech integration into healthcare increases the efficacy of the clinical trials, both companies should be able to launch multiple new drugs in the market soon.

Continue reading on StockNews

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.


Most Related Links :
Business News Governmental News Finance News

Need Your Help Today. Your $1 can change life.

[charitable_donation_form campaign_id=57167]

Source link

Back to top button